Use of an expression inhibitor of miR-8072 in the preparation of a drug for treating er-positive breast cancer

By targeting and inhibiting miR-8072, the expression inhibitor of miR-8072 enhances the sensitivity of ER-positive breast cancer cells to tamoxifen, solving the problem of tamoxifen resistance and achieving the effect of personalized treatment.

CN122182772APending Publication Date: 2026-06-12NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
Filing Date
2026-03-05
Publication Date
2026-06-12

AI Technical Summary

Technical Problem

In the current technology, about 30%-40% of ER-positive breast cancer patients develop unexplained drug resistance after long-term use of tamoxifen, leading to disease recurrence and poor prognosis. There is a lack of effective molecular targets to overcome tamoxifen resistance.

Method used

By using miR-8072 expression inhibitors, including miR-8072 antisense oligonucleotides or antagonists, to enhance the sensitivity of ER-positive breast cancer cells to tamoxifen through targeted inhibition of miR-8072, a drug for the treatment of ER-positive breast cancer was prepared.

Benefits of technology

Inhibitors of miR-8072 expression can significantly enhance the sensitivity of ER-positive breast cancer cells to tamoxifen, inhibit their growth, overcome tamoxifen resistance, achieve personalized treatment goals, and avoid the limitations of traditional intervention models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122182772A_ABST
    Figure CN122182772A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to application of an expression inhibitor of miR-8072 in preparation of an ER-positive breast cancer treatment drug. It is found for the first time that overexpression of miR-8072 causes estrogen receptor-positive breast cancer to be resistant to tamoxifen. Targeted inhibition of miR-8072 expression for treatment is an effective way to resist tamoxifen resistance in estrogen receptor-positive breast cancer.
Need to check novelty before this filing date? Find Prior Art